Johnson & Johnson’s JNJ multibillion-dollar immunology drug, Stelara, lost patent exclusivity in the United States this year.

Biosimilar drugmaker Alvotech ALVO has positioned itself differently from other players in the space by using partnerships as ...

Learn more about whether Alvotech or Travere Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibault Boutherin. I am co-head of the European Pharma Equity Research team based in London. Before we ...

Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its ...

REYKJAVIK, Iceland, June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its ...

August 2025 brought significant advancements in biosimilars, including financial successes, new product launches, and research on ongoing challenges in market access.

Mynzepli ® (aflibercept) is approved in all European Economic Area member countries for the treatment of various retinal diseases including neovascular (wet) age-related macular degeneration (AMD) ...

Strong performance driven by over 200% growth in product revenues year-on-yearBest quarter in Alvotech’s history in terms of operating cash flowsContinued expansion of commercial partnerships for ...

Alvotech will integrate Ivers-Lee’s operations into its Technical Ops to boost biosimilar production. Ivers-Lee will continue as a standalone entity while supporting Alvotech’s 2025 product launches.

HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...